British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million.

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

After second devaluation of the naira, manufacturers overhauled supply chains to source more materials domestically ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

Mumbai: In a major relief for Thermo Fisher Scientific India Pvt. Ltd., the Income Tax Appellate Tribunal (ITAT), Mumbai "H" ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

The medical world relies on horseshoe crab blood in the production of vaccines and equipment. A synthetic is available, but ...

Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.